Kyverna Therapeutics, Inc.KYTXNASDAQ
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
133.27%
↑ 150% above average
Average (3y)
53.22%
Historical baseline
Range
High:133.27%
Low:0.00%
Volatility
250.4%
High variability
| Period | Value |
|---|---|
| 2024 | 133.27% |
| 2023 | 69.76% |
| 2022 | 9.86% |
| 2021 | 0.00% |